Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEONAX: Perioperative vs Adjuvant Nab-Paclitaxel/Gemcitabine for Pancreatic Cancer
NCT02047513Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jul 2015
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by AIO-Studien. Started Jul 2015; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02047513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047513.